Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
JAZZ
JAZZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest JAZZ ETF News Today | Earnings, Events & Price Alerts
JAZZ News
Analysis of Growth Drivers in the Biliary Tract Cancer Market
2d ago
Newsfilter
Zymeworks Secures $250 Million Royalty-Backed Financing
2d ago
Yahoo Finance
Wall Street Analysts Adjust Ratings
5d ago
Benzinga
Key Wall Street Calls on Friday: Upgrades and Downgrades
5d ago
CNBC
MasTec and Jazz Pharmaceuticals See Active Options Trading
Feb 25 2026
NASDAQ.COM
Jazz Pharmaceuticals Reports Record Q4 2025 Earnings and Strategic Focus on Rare Diseases
Feb 25 2026
seekingalpha
Jazz Pharmaceuticals to Participate in Investor Conferences
Feb 17 2026
PRnewswire
Jazz Pharmaceuticals to Report Q4 and Full Year 2025 Results
Feb 10 2026
PRnewswire
Harmony Biosciences: Financial Success Amidst Challenges
Jan 27 2026
Fool
Harmony's Wakix Drug: Financial Success Amid Controversy
Jan 27 2026
NASDAQ.COM
Zymeworks (ZYME) 2026 Milestones Expected to Drive Long-Term Value with Promising ZW191 Data
Jan 12 2026
NASDAQ.COM
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
Jan 08 2026
PRnewswire
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer to Drive Strategic Development
Jan 08 2026
Newsfilter
Jazz Pharmaceuticals Reports Ziihera Trial Shows Significant Survival Benefits
Jan 07 2026
Benzinga
Jazz Pharmaceuticals Reports Positive HERIZON-GEA-01 Trial Results for Ziihera in Cancer Treatment
Jan 07 2026
NASDAQ.COM
Jazz Pharmaceuticals' Ziihera Therapy Significantly Improves Survival in HER2+ Gastric Cancer
Jan 06 2026
Newsfilter
Show More News
